Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors Clinical Trial

Official title:

A Phase II Study of Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: Imatinib Dose Escalation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01541709
• Other study ID #: AMC1102
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 2012
• Est. completion date: December 31, 2024

Study information

• Verified date: December 2023
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

KIT exon 9 mutants had poorer survival compared with KIT exon 11 mutants when they were treated with the same dose of imatinib, 400 mg per day, and that patients with KIT exon 9 mutation had better progression-free survival with imatinib treatment at an escalated dose, 800 mg per day, than with imatinib treatment at a dose of 400 mg per day.10,11 Based on the results, imatinib 800 mg per day is now considered the standard dose for the treatment of patients with metastatic or unresectable GIST showing KIT exon 9 mutation in Western countries.

Description:

According to our previous prospective phase II study of imatinib 400 mg per day in metastatic or unresectable GIST, hematologic and non-hematologic toxicities were more frequent in Korean patients compared to the Western studies.7 It may be caused by relatively higher exposure to imatinib per body surface area in Korean patients than in Western population because the weight and height of Korean patients are relatively smaller than Western people. So, we plan to start imatinib at 400 mg per day and then sequentially escalate the doses of imatinib in this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 23
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or older

• Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1 (+), or KIT mutation

• ECOG PS(Eastern Cooperative Oncology Group Performance Status) 0~2

• Primary mutation at KIT exon 9

• Imatinib treatment for less than 4 weeks from the first dose at 400 mg per day

• No prior use of tyrosine kinase inhibitors ((but, patients who have recurrence 6 months after completion of adjuvant imatinib at a dose of 400 mg per day can be enrolled in this study)

• At least one evaluable disease by RECIST v1.0

• Resolution of all toxic effects of prior treatments (chemotherapy, surgery, RFA(radiofrequency ablation), radiotherapy, and/or TACE)

• Adequate bone marrow function as defined by platelets = 75 x 109/L and neutrophils = 1.5 x 109/L (within 1 week prior to the first dose of imatinib at 400 mg per day)

• Adequate renal function, with serum creatinine < 1.5 x ULN (within 1 week prior to the first dose of imatinib at 400 mg per day)

• Adequate hepatic function with serum total bilirubin < 1.5 x ULN, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases, or < 5 x UNL in the presence of liver metastases (within 1 week prior to the first dose of imatinib at 400 mg per day)

• No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other cancer except where treated with curative intent > 5 years previously without evidence of relapse

• Provision of a signed written informed consent

Exclusion Criteria:

• Severe co-morbid illness and/or active infections

• Pregnant or lactating women

• History of other malignancies except basal cell carcinoma and carcinoma in situ of uterine cervix

• CNS metastasis

• Clinically significant bleeding in GI tract

• GI obstruction or malabsorption

• Known hypersensitivity to imatinib

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumors

Intervention

Drug:
• imatinib
The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center, University of Ulsan College of Medicine	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression-free survival (PFS)	evaluated with Triphasic or dynamic CT scans of abdomen & pelvis, and other involved sites. Follow-up CT scans will be performed at 4 weeks and 12 weeks after the first dose of imatinib at 400 mg per day, and then every 3 months until disease using RECIST(Response Evaluation Criteria in Solid Tumors) version 1.0	up to 24months
Secondary	disease control rate		Up to 24weeks
Secondary	safety control rate		up to 24months
Secondary	overall survival (OS)		up to 24months
Secondary	imatinib PK(pharmacokinetics) (Cmin)		up to 24months
Secondary	percentage of successful dose escalation		up to 24months